Quantum BioPharma (QNTM)
Develops clinical-stage treatments while retaining investments and consumer-product economics.
Something off on this page? Send us feedback.
Develops experimental treatments led by Lucid-MS for multiple sclerosis, alongside FSD-PEA for mast-cell activation syndrome. The company also reports a strategic-investments segment and retains economic interests in unbuzzd, a spun-out consumer product.
Clinical-stage development centers on Lucid-MS, an investigational compound directed at myelin degradation in multiple sclerosis. FSD-PEA is also in development for mast-cell activation syndrome, within a portfolio that targets neurodegenerative, inflammatory, metabolic, and alcohol-misuse disorders.
A separately reported strategic-investments segment sits alongside biopharmaceutical R&D. The company retained ownership and royalty economics in unbuzzd after spinning its consumer rights into Unbuzzd Wellness, while keeping pharmaceutical and medical-formulation rights.
From Toronto, founder and CEO Zeeshan Saeed leads the company. Progress depends on clinical development, regulatory authorization, financing, intellectual-property protection, and continued exchange-listing compliance.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.7M · Total debt $962.2K · Total assets $14.4M · Shareholders' equity $7.9M
- Revenue
- $0
- Operating income
- −$2.2M
- Net income
- −$3.2M
No dividends on record.
| Institutions24 holders · as of Mar 31, 2026 | 3.97% | 254.3K shares | |
| Otherremainder | 96.03% | 6.14M shares |
6.40M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Advisorshares Investments LLCInstitution | 1.70% | 108,591 | 13Fas of Mar 31, 2026 |
Platform Technology PartnersInstitution | 0.64% | 41,116 | 13Fas of Mar 31, 2026 |
Jane Street Group, LLCInstitution | 0.49% | 31,501 | 13Fas of Mar 31, 2026 |
Citadel Advisors LLCInstitution | 0.25% | 15,863 | 13Fas of Mar 31, 2026 |
Marex Group PLCInstitution | 0.21% | 13,468 | 13Fas of Mar 31, 2026 |
| See all 24 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Novartis (ADR)
Approved and pipeline therapies spanning relapsing and progressive MS
- Biogen
Established portfolio of marketed multiple-sclerosis therapies
- TG Therapeutics
Commercial and clinical programs across relapsing and progressive MS
- Immunic
Late-stage oral therapy program for relapsing and progressive MS
- Clene
Clinical remyelination and neuroprotection programs in multiple sclerosis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quantum BioPharma | $3.12 | +2.63% | $19.7M | — | — | — | — |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| TG Therapeutics | $56.50 | −0.70% | $8.71B | 20.8 | 29.9 | 10.9 | +70.3% |
| Immunic | $14.23 | −2.40% | $194.0M | — | — | — | — |
| Clene | $4.19 | +2.07% | $53.2M | — | — | 269.8 | +233.3% |
| Median | 24.5 | 17.3 | 8.3 | +36.8% |